Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

3TC treatment may slow HIV mutations, development of drug resistance.

NIAID AIDS agenda - 1 Mar 1996

Abstract excerpt

According to a recent study conducted by the Albert Einstein College of Medicine, HIV develops a mutation (M184V) in patients treated with 3TC (lamivudine). The mutation appears to be resistant to 3TC but decreases the rate at which other mutations develop. Researchers are hopeful that the slowed rate of variation of HIV will be an advantage to the immune system's ability to suppress the virus. In cell culture...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Microbial
Share to HIV
Share to HIV Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lamivudine

Share to Mutation

Share to Zalcitabine

Source

Identifiers

PMID: 11363803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

3TC treatment may slow HIV mutations, development of drug resistance.PMID 11363803Read ↗

Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.Semantic proximity Read ↗

The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.Semantic proximity Read ↗

The multiple benefits associated with HIV drug-resistance mutation M184V.Semantic proximity Read ↗

Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.Semantic proximity Read ↗

Might the M184V substitution in HIV-1 RT confer clinical benefit?Semantic proximity Read ↗

Resistance: how HIV evolves to survive.Semantic proximity Read ↗

Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.Semantic proximity Read ↗

The impact of the M184V substitution on drug resistance and viral fitness.Semantic proximity Read ↗

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.Semantic proximity Read ↗

Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.Semantic proximity Read ↗

Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.Semantic proximity Read ↗

Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: the Relative Roles of Drift and SelectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.